Pediatric vaccine market size was valued at $21.4 billion in 2021, and is estimated to reach $36.4 billion by 2031, growing at a CAGR of 5.4% from 2022 to 2031. Pediatric vaccines are administered to a child in their pediatric age, which is from 0โ€“18 years. Vaccines are generally given to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, vaccines are administered at regular intervals.ย  WHO has designed a standard immunization program to have desired time interval between vaccines doses.

๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ :

Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis


๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/438


Pediatric vaccines marketย  include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine, and meningococcal vaccine. Pneumococcal vaccine is administered to prevent child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.

Key factors that drive the growth of the pediatric vaccine market sizeย is increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines. Moreover, favorable reimbursement and increasing government support is further expected to boost the market growth during forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates is likely to hamper the growth of the pediatric vaccine market during the forecast period. Conversely, rise in demand in emerging markets, increase in R&D activities to develop new vaccines in the pediatric vaccine industry, and surge in healthcare spending are expected to provide numerous opportunities for market growth during the pediatric vaccine market forecast.

๐๐ฎ๐ฒ ๐๐จ๐ฐ https://www.alliedmarketresearch.com/checkout-final/585b9604012c7da97690c2c6bdb502d3

Depending on technology, the subunit, recombinant, polysaccharide, and conjugate vaccines segment has largest contribution in pediatric vaccine market share in 2021, and is expected to remain dominant during the forecast period, owing to these vaccines are considered to be the most efficient alternative to traditional vaccines in the prevention of various human diseases. In addition, the increase in number of regulatory clearances have made the highest impact on the market in recent years.

By indication, the pneumococcal segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to introduction of novel pneumococcal vaccines in the market, initiatives taken by governments such various immunization programs for pneumonia, and rise in awareness among patients regarding pneumococcal vaccines.

Region wise, pediatric vaccine market analysis across North America, Europe, Asia-Pacific and LAMEA. North America has the highest market share, with $9,018.87 million in 2021, and is estimated to reach $14,265.27 million by 2031, registering a CAGR of 4.7% during the forecast period. Owing to the investments made by the key players in pediatric vaccine industry for various R&D activities as well as launch of new products in the U.S. In addition, extensive research in pharmaceutical and biotechnology companies is further anticipated to stimulate growth of the pediatric vaccines market in North America. Asia pacific is projected to register the highest CAGR of 6.9% during the pediatric vaccine market forecast period. high burden of pediatric diseases, increase in affordability, and improvements in healthcare access in developing countries such as India and China are the key driving factors that boost the growth of the pediatric vaccine industry in the region.


๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/438


๐Š๐„๐˜ ๐…๐ˆ๐๐ƒ๐ˆ๐๐†๐’ ๐Ž๐… ๐“๐‡๐„ ๐’๐“๐”๐ƒ๐˜

  •  On the basis of type, the monovalent segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • On the basis of technology, the subunit, recombinant, polysaccharide, and conjugate vaccines segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • Depending on indication, pneumococcal segment is projected to grow at a CAGR of 3.5% during the forecast period.
  • Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 6.9% during the forecast period.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Leave a comment

Your email address will not be published. Required fields are marked *